Recurrence rate and progression of chondrosarcoma is correlated with heat shock protein expression

Trieb,Klemens; Sulzbacher,Irene; Kubista,Bernd

doi:10.3892/ol.2015.3926

Recurrence rate and progression of chondrosarcoma is correlated with heat shock protein expression

Authors:
- Klemens Trieb
- Irene Sulzbacher
- Bernd Kubista
View Affiliations

Affiliations: Department of Orthopaedics, Hospital Wels‑Grieskirchen, Wels A‑4600, Austria, Department of Pathology, University Hospital of Vienna, Vienna A‑1090, Austria, Department of Orthopaedics, University Hospital of Vienna, Vienna A‑1090, Austria
Published online on: November 17, 2015 https://doi.org/10.3892/ol.2015.3926
Pages: 521-524
Copyright: © Trieb et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Heat shock proteins (HSPs) are involved in tumour immunity, and are correlated with survival and drug resistance in numerous types of cancer. The present study investigated the expression of HSPs and multiple drug resistance (MDR) in human chondrosarcoma. HSP and P‑glycoprotein (the MDR1 gene product) expression was evaluated by immunohistochemical analysis of paraffin‑embedded sections obtained from 37 patients with chondrosarcoma (19 male and 18 female; aged 33‑85 years; mean age, 48.5 years). HSP73 and 90 were significantly overexpressed in patients with local recurrence: HSP73 was expressed in 7/7 patients (100%) with local recurrence and 9/18 patients (50%) without recurrence (P<0.02), while HSP90 was expressed in all patients with recurrence but only 8/18 (44%) without recurrence (P<0.02). A marked association was also identified between HSP expression and survival. HSP72 and 73 were significantly overexpressed in tumours from patients who succumbed to the disease (all positive for HSP72 and 73; P<0.05). No differences were observed between HSP27, 73 or 90‑positive or ‑negative tumours according to age or gender. In addition, HSP72 expression was correlated with differentiation of the tumours (P<0.02). These results indicate that HSP72, 73 and 90 may function as novel prognostic markers for chondrosarcoma, and initiate further studies regarding the use of such markers for the identification of patients with poor prognosis.

View Figures

View References

1	Sheth DS, Yasko AW, Johnson ME, Ayala AG, Murray JA and Romsdahl MM: Chondrosarcoma of the pelvis. Prognostic factors for 67 patients treated with definitive surgery. Cancer. 78:745–750. 1996. View Article : Google Scholar : PubMed/NCBI
2	Evans HL, Ayala AG and Romsdahl MM: Prognostic factors in chondrosarcoma of bone: A clinicopathologic analysis with emphasis on histologic grading. Cancer. 40:818–831. 1977. View Article : Google Scholar : PubMed/NCBI
3	Kreicbergs A, Boquist L, Borssén B and Larsson SE: Prognostic factors in chondrosarcoma: A comparative study of cellular DNA content and clinicopathologic features. Cancer. 50:577–583. 1982. View Article : Google Scholar : PubMed/NCBI
4	Springfield DS, Gebhardt MC and McGuire MH: Chondrosarcoma: A review. Instr Course Lect. 45:417–424. 1996.PubMed/NCBI
5	Ayala AG, Ro JY, Han W, Sahin A and Raymond AK: Chondrosarcoma: A clinocopathologic study of 173 cases with a minimal 5 years follow-up. Lab Invest. 64:2A1991.
6	Shin KH, Rougraff BT and Simon MA: Oncologic outcomes of primary bone sarcomas of the pelvis. Clin Orthop Relat Res. 304:207–217. 1994.PubMed/NCBI
7	Trieb K, Gerth R, Holzer G, Grohs JG, Berger P and Kotz R: Antibodies to heat shock protein 90 in osteosarcoma patients correlate with response to neoadjuvant chemotherapy. Br J Cancer. 82:85–87. 2000. View Article : Google Scholar : PubMed/NCBI
8	Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R and Dirnhofer S: Heat shock protein 72 expression in osteosarcomas correlates with good response to neoadjuvant chemotherapy. Hum Pathol. 29:1050–1055. 1998. View Article : Google Scholar : PubMed/NCBI
9	Trieb K, Kohlbeck R, Lang S, Klinger H, Blahovec H and Kotz R: Heat shock protein 72 expression in chondrosarcoma correlates with differentiation. J Cancer Res Clin Oncol. 126:667–670. 2000. View Article : Google Scholar : PubMed/NCBI
10	Welch WJ: Mammalian stress response: Cell physiology, structure/function of stress proteins, and implications for medicine and disease. Physiol Rev. 72:1063–1081. 1992.PubMed/NCBI
11	Jäättelä M and Wissing D: Emerging role of heat shock proteins in biology and medicine. Ann Med. 24:249–258. 1992. View Article : Google Scholar : PubMed/NCBI
12	Lindquist S and Craig EA: The heat-shock proteins. Annu Rev Genet. 22:631–677. 1988. View Article : Google Scholar : PubMed/NCBI
13	Arrigo AP and Landry J: Expression and function of the low-molecular-weight heat shock proteins. The Biology of Heat Shock Proteins and Molecular Chaperones. Morimoto R, Tissieres A and Georgopoulos C: (New York, NY). Cold Spring Harbor Press. 335–373. 1994.
14	Kaufmann SH: Heat shock proteins and the immune response. Immunol Today. 11:129–136. 1990. View Article : Google Scholar : PubMed/NCBI
15	Udono H and Srivastava PK: Heat shock protein 70-associated peptides elicit specific cancer immunity. J Exp Med. 178:1391–1396. 1993. View Article : Google Scholar : PubMed/NCBI
16	Multhoff G, Botzler C, Jennen L, Schmidt J, Ellwart J and Issels R: Heat shock protein 72 on tumor cells: A recognition structure for natural killer cells. J Immunol. 158:4341–4350. 1997.PubMed/NCBI
17	Gromkowski SH, Yagi J and Janeway CA Jr: Elevated temperature regulates tumor necrosis factor-mediated immune killing. Eur J Immunol. 19:1709–1714. 1989. View Article : Google Scholar : PubMed/NCBI
18	Guénal I, Sidoti-de Fraisse C, Gaumer S and Mignotte B: Bcl-2 and Hsp27 act at different levels to suppress programmed cell death. Oncogene. 15:347–360. 1997. View Article : Google Scholar : PubMed/NCBI
19	Conroy SE and Latchman DS: Do heat shock proteins have a role in breast cancer? Br J Cancer. 74:717–721. 1996. View Article : Google Scholar : PubMed/NCBI
20	Wunder JS, Bull SB, Aneliunas V, et al: MDR1 gene expression and outcome in osteosarcoma: A prospective, multicenter study. J Clin Oncol. 18:2685–2694. 2000.PubMed/NCBI
21	Borst P: Genetic mechanisms of drug resistance. A review. Acta Oncol. 30:87–105. 1991. View Article : Google Scholar : PubMed/NCBI
22	Gottesman MM and Pastan I: Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
23	Endicott JA and Ling V: The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem. 58:137–171. 1989. View Article : Google Scholar : PubMed/NCBI